



These additions and changes are effective 2/14/25

Pharmacy Benefit Additions (these apply to Exchange only):

Tryvio (aprocitentan)– Pharmacy benefit, Non-Preferred brand, PA

Duvyzat (givinostat)– Pharmacy benefit, Non-Preferred brand, PA

Sofdra (sofpironium) – Pharmacy benefit, Non-Formulary

Vafseo (vadadustat) – Pharmacy benefit, Non-Preferred brand, PA

Iqirvo (elafibranor) – Pharmacy benefit, Non-Preferred brand, PA

Ohtuvayre (ensifentrine) – Pharmacy benefit, Non-Preferred brand, PA

Lazcluze (Lazertinib) – Pharmacy benefit, Non-Preferred brand, PA

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Kisunla (donanemab-azbt) – Medical benefit, PA

Anktiva (nogapendekin alfa inbakicept) – Medical benefit, PA

Vyloy (zolbetuximab-clzb) – Medical benefit, PA

Tremfya IV (guselkumab) – Medical benefit, PA, new formulation

Ocrevus Zunovo SQ (oxrerlizumab and hyaluronidase-ocsq) – Medical benefit, PA, new formulation

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) – Medical benefit, PA, new formulation

Pavblu (aflibercept-ayyh) – Medical benefit, PA